| Meghan D Rearden, SLP | |
|
161 Klevin St, Suite 103, Anchorage, AK 99508-1508 | |
| (907) 561-8060 | |
| (907) 563-3172 |
| Full Name | Meghan D Rearden |
|---|---|
| Gender | Female |
| Speciality | Speech-language Pathologist |
| Location | 161 Klevin St, Anchorage, Alaska |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1982891008 | NPI | - | NPPES |
| 7018518 | Medicaid | WA |
| Mailing Address | Practice Location Address |
|---|---|
| Meghan D Rearden, SLP Po Box 190675, Anchorage, AK 99519-0675 Ph: (907) 282-4044 | Meghan D Rearden, SLP 161 Klevin St, Suite 103, Anchorage, AK 99508-1508 Ph: (907) 561-8060 |
News Archive
Admedus today announced it has received FDA clearance to market CardioCel in the US. CardioCel is the group's lead regenerative tissue product to repair and treat a range of cardiovascular and vascular defects. The Company will now look to complement its existing product launch in Europe with preparation for initial sales in the US.
New research published in the International Journal of Food Science and Technology found steviol glycosides are not altered during the extraction and purification process to make high-purity stevia extract.
In the May 3 issue of the Journal of the American Medical Association, Brian L. Strom, MD, MPH, Professor of Public Health and Preventive Medicine and Chair of the Department of Biostatistics and Epidemiology at the University of Pennsylvania School of Medicine, analyzes the limitations of the current system of drug-safety monitoring and proposes a solution that addresses overly aggressive early marketing practices
Bolder BioTechnology, Inc. today announced that it has been awarded a total of $1.2 million in Qualifying Therapeutic Discovery Project Grants. Grants were awarded for qualified investments under the Qualifying Therapeutic Discovery Project Tax Credit Program, which authorized up to $1 billion in tax credits or grants to biopharmaceutical companies with 250 or fewer employees.
Apexigen, Inc., a biopharmaceutical company discovering and developing innovative antibody drugs for the treatment of cancer and other life-threatening diseases, announced today the initiation of a Phase 1 clinical trial of APX005M, the company's lead proprietary anticancer program.
› Verified 8 days ago
Kathryn Cross, CCC-SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 12350 Industry Way, 202, Anchorage, AK 99515 Phone: 907-301-4588 | |
Tracey Keaton, SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 6927 Old Seward Hwy Ste 100, Anchorage, AK 99518 Phone: 907-345-0050 | |
Christal Hays, MS CCC SLP Speech-Language Pathologist Medicare: Medicare Enrolled Practice Location: 4441 Diplomacy Dr, Anchorage, AK 99508 Phone: 907-729-8800 | |
Mrs. Lisa J.c. Rayes, CCC-SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 4048 Laurel St Ste 303, Anchorage, AK 99508 Phone: 907-562-4550 | |
Lian Liew Tan, SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 4155 Tudor Centre Dr, Suite #103, Anchorage, AK 99508 Phone: 907-854-8624 | |
Mrs. Yvonne Marie San Juan, M.S., CCC-SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 4241 B St Ste 301, Anchorage, AK 99503 Phone: 907-727-0935 Fax: 907-276-7529 | |
Speak From The Heart Llc Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 3351 W 84th Ave, Anchorage, AK 99502 Phone: 907-390-0492 |